Statistics
The Prothena Corporation plc stock price is currently $ 8.16 with a total market cap valuation of $ 419.01M (51.35M shares outstanding). The Prothena Corporation plc is trading on NASDAQ under the ticker sign PRTA. Prothena Corporation plc price is up
Description
Established in 2012 and headquartered in Dublin, Ireland, Prothena Corporation plc functions as a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapeutic solutions for critical, life-threatening conditions, primarily within the United States. The company's pipeline features several key programs: Birtamimab, an investigational humanized antibody, is currently undergoing Phase III clinical trials for the treatment of AL amyloidosis. Prasinezumab, a humanized monoclonal antibody, is progressing through Phase IIb trials for Parkinson's disease. Prothena has also completed Phase I clinical trials for PRX004, indicated for Transthyretin amyloidosis, and is advancing PRX005 through Phase I for Alzheimer's disease. In its earlier-stage development, Prothena is exploring PRX012 for Alzheimer's disease, alongside a dual Aß-Tau vaccine designed for both the treatment and prevention of Alzheimer's disease. Prothena maintains strategic partnerships, including a comprehensive license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. for antibodies targeting alpha-synuclein. The company also collaborates with Bristol-Myers Squibb on antibody development.
Company Profile
- Full Name: Prothena Corporation plc
- Sector: Healthcare
- Website: https://www.prothena.com
